PA-MSHA辅助治疗晚期胃癌的效果观察  

Effect obervation of PA-MSHA vaccine joint therapy for advanced gastric cancer

作　　者：刘怀民[1] 杨峰[1] 刘晓莉[1] 

机构地区：[1]河南省肿瘤医院,郑州450008

出　　处：《医药论坛杂志》2011年第8期34-36,共3页Journal of Medical Forum

摘　　要：目的观察PA-MSHA辅助奥沙利铂联合ELF（足叶乙甙加亚叶酸钙加5-氟尿嘧啶）方案对晚期胃癌的治疗疗效并评估不良反应。方法选择我院手术病理证实为晚期胃腺癌患者40例。患者均在术后第15d开始奥沙利铂联合ELF化疗方案（奥沙利铂100mg/m2,静滴2h,第1d;亚叶酸钙200mg/m2,静滴30min,第1~3d;5-氟尿嘧啶500mg/m2,静滴2h,第1~3d;足叶乙甙100mg/m2,静滴3h,第1~3d）治疗,间隔21d进行第二个周期该化疗方案;术后当日开始皮下注射万特普安,1ml/d×7d,以后隔日1次,持续到术后1个月;术后化疗前3个周期后评价疗效和不良反应。结果所有病例均可评价疗效,其中完全缓解（CR）4例,部分缓解（PR）19例,病情稳定（SD）14例,病情进展（PD）3例,总缓解率为57.5%。主要的血液学不良反应为贫血（57.5%）、白细胞减少（37.5%）和血小板减少（45%）。最常见的非血液学不良反应有恶心呕吐（52.5%）、口腔黏膜炎（30%）、腹泻（42.5%）和脱发（12.5%）。KPS提高20分以上者47.5%（19/40）。结论 PA-MSHA辅助奥沙利铂联合ELF方案可通过减少晚期胃癌术后机体对ELF化疗方案化疗不良反应,增强对化疗耐受性,而增强该方案的化疗疗效。Objective To evaluate the effect of pseudomonas aeruginous MSHA（PA-MSHA）vaccine and ELF plus oxaliplatin on advanced gastric cancer.Methods Totally 40 cases of advanced gastric adenocarcinoma confirmed by pathology were selected in our hospital.All cases began chemotherapy with the 15 days after sugery（oxaliplatin 100 mg/m2,iv 2hrs,the first day;calcium folinate 200 mg/m2,iv 30mins,from the first day to the third day;5-FU 500 mg/m2,iv 2hrs,from the first day to the third day;etoposide 100 mg/m2,iv 3hrs,from the first day to the third day）.Repeated the same treatment after 21 day of the first treatment.A total of 3 cycles of treatment were done.PA-MSHA were treatment subcutaneous injection with the dose of 1ml per day from the day of postoperative to 7 days after surgery,1ml every other day until the 30 days after surgery.Evaluated the effective and adverse reaction of the treatment when the third of chemotherapy were over.Results All cases were evaluated,4 cases were CR,19 cases were PR,14 cases were SD and 3 cases were PD,remission rate altogether were 57.5%.Major hematologic adverse reactions were anemia（57.5%）,leucopenia（37.5%）,and thrombocytopenia（45%）.Other adverse reactions were nausea and vomiting（52.5%）,oral mucocitis（30%）,diarrhea（42.5%） and baldness（12.5%）.42.5% patients＇ KPS increased to 20 or above 20.Conclusions PA-MSHA could enhance the effect of oxaliplatin combined with ELF scheme by decreasing the adverse effective and improving the tolerance to the scheme.

关 键 词：PA-MSHA 奥沙利铂 ELF方案 胃癌 

分 类 号：R735.2[医药卫生—肿瘤]